Payment overview · 2025
General Payments
$1,884.14
57 reported records · 13 companies
Healthcare provider profile · identity verified
Phi Tan Huynh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LODI, CA · NPI 1598742413
Verified facts
What the public records show
CMS Open Payments records show Phi Tan Huynh, MD received $1,884.14 in general payments during 2025 across 57 reported records.
Amgen Inc. accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Rybelsus, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $597.29 | 31.7% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $394.80 | 20.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $229.74 | 12.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $207.41 | 11.0% | 9 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $144.76 | 7.7% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.50 | 6.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $45.08 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.98 | 2.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.16 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.93 | 1.2% | 1 | 2025 |
| RedHill Biopharma Inc. | Unresolved — no canonical attribution shown | $21.86 | 1.2% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $16.57 | 0.9% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,884.14 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $332.21 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $275.33 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $234.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $221.60 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $209.41 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $207.41 | 9 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $144.76 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $123.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $88.38 | 6 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $26.70 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Talicia Normalized: talicia |
Drug | RedHill Biopharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 263 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
75 | 46 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
98 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
263 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 759 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 148 |
| Losartan Potassium | Losartan Potassium | 364 | 116 |
| Metformin Hcl Er | Metformin Hcl | 349 | 105 |
| Fluticasone Propionate | Fluticasone Propionate | 345 | 98 |
| Jardiance | Empagliflozin | 263 | 48 |
| Naproxen | Naproxen | 259 | 120 |
| Alendronate Sodium | Alendronate Sodium | 228 | 66 |
| Famotidine | Famotidine | 225 | 95 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 215 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 69 |
| Metformin Hcl | Metformin Hcl | 191 | 57 |
| Gabapentin | Gabapentin | 173 | 65 |
| Montelukast Sodium | Montelukast Sodium | 165 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 51 |
| Atenolol | Atenolol | 136 | 38 |
| Fenofibrate | Fenofibrate | 125 | 37 |
| Lisinopril | Lisinopril | 124 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 57 |
| Farxiga | Dapagliflozin Propanediol | 98 | 17 |
| Ibuprofen | Ibuprofen | 97 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 30 |
| Trazodone Hcl | Trazodone Hcl | 86 | 35 |
| Methylprednisolone | Methylprednisolone | 79 | 71 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 17 |
| Baclofen | Baclofen | 76 | 54 |
| Prolia | Denosumab | 75 | 46 |
| Hydrocortisone | Hydrocortisone | 74 | 23 |
| Omeprazole | Omeprazole | 74 | 28 |
| Azithromycin | Azithromycin | 73 | 69 |
| Celecoxib | Celecoxib | 71 | 27 |
| Loperamide | Loperamide Hcl | 68 | 53 |
| Finasteride | Finasteride | 63 | 18 |
| Januvia | Sitagliptin Phosphate | 63 | 11 |
| Amoxicillin | Amoxicillin | 61 | 57 |
| Cromolyn Sodium | Cromolyn Sodium | 61 | 22 |
| Lovastatin | Lovastatin | 60 | 15 |
| Colchicine | Colchicine | 59 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 54 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 23 |
| Donepezil Hcl | Donepezil Hcl | 57 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 30 |
| Simvastatin | Simvastatin | 55 | 17 |
| Allopurinol | Allopurinol | 52 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 51 | 14 |
| Meclizine Hcl | Meclizine Hcl | 51 | 41 |
| Mirtazapine | Mirtazapine | 51 | 18 |
| Cephalexin | Cephalexin | 47 | 44 |
| Sildenafil Citrate | Sildenafil Citrate | 47 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | 28 |
| Entecavir | Entecavir | 41 | suppressed |
| Prednisone | Prednisone | 39 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 36 |
| Benazepril Hcl | Benazepril Hcl | 38 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 14 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 16 |
| Kerendia | Finerenone | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Invokana | Canagliflozin | 28 | suppressed |
| Lactulose | Lactulose | 28 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | 12 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 22 | 21 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 22 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Proctozone-Hc | Hydrocortisone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Benzonatate | Benzonatate | 16 | 15 |
| Linzess | Linaclotide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Indomethacin | Indomethacin | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,884.14 · 57 records | Amgen Inc. | AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, EVENITY, GARDASIL 9, ISTURISA, JARDIANCE, KRYSTEXXA, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, Talicia, VOQUEZNA, Xhance, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error